TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE

膀胱癌（BC）是泌尿生殖道第二常见的癌症，也是患者死亡的主要原因。预防BC对于减少复发率、死亡率和提高生活质量是非常可取的。临床前和临床数据表明AR信号在BC不同阶段的潜在作用。鉴于AR信号与膀胱癌进展之间的紧密联系，apalutamide作为FDA批准的下一代AR拮抗剂，可以为NMIBC提供预防策略，以减缓进展到MIBC。本课题的总体目标是确定阿帕鲁胺对n -丁基- n（4-羟基丁基）亚硝胺（BBN）诱导的大鼠膀胱癌的疗效。该任务订单将评估阿帕鲁胺抑制膀胱癌的明确预测生物标志物。

Bladder cancer (BC) is the second-most common cancer of the genitourinary tract and also the major cause of death in patients. Preventing BC is highly desirable to reduce recurrence, mortality and improve quality of life. Preclinical and clinical data indicate the potential role of AR signaling in different stages of BC. In view of the strong link between AR signals and bladder cancer progression, apalutamide, a FDA approved next-generation AR antagonist, could provide a preventive strategy in NMIBC to mitigate progression to MIBC. The overall objective of this task order is to determine the efficacy of Apalutamide against N-butyl-N(4-hydroxybutyl) nitrosamine (BBN) induced rat urinary bladder cancers. The task order will assess welldefined predictive biomarkers of bladder cancer inhibition by apalutamide.